|
YARS expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | <1E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.62436730732907E-12 |
| Normal-vs-Stage2 |
1.09220000044097E-07 |
| Normal-vs-Stage3 |
1.62481139653892E-12 |
| Normal-vs-Stage4 |
5.79990000471042E-08 |
| Stage1-vs-Stage2 |
9.928500E-02 |
| Stage1-vs-Stage3 |
1.486330E-02 |
| Stage1-vs-Stage4 |
4.575000E-01 |
| Stage2-vs-Stage3 |
1.276370E-02 |
| Stage2-vs-Stage4 |
4.981000E-01 |
| Stage3-vs-Stage4 |
4.635800E-02 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.62447832963153E-12 |
| Normal-vs-AfricanAmerican |
1.98430000208916E-08 |
| Normal-vs-Asian |
1.34930000506017E-08 |
| Caucasian-vs-AfricanAmerican |
9.893400E-01 |
| Caucasian-vs-Asian |
5.297200E-01 |
| AfricanAmerican-vs-Asian |
5.801800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.77236045021345E-15 |
| Normal-vs-Female |
1.11022302462516E-16 |
| Male-vs-Female |
1.596230E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
<1E-12 |
| Normal-vs-Age(41-60Yrs) |
1.62458935193399E-12 |
| Normal-vs-Age(61-80Yrs) |
3.65263375101677E-14 |
| Normal-vs-Age(81-100Yrs) |
5.86550000000186E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.194000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
5.216600E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
5.910400E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
1.988050E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.124650E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.603800E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
6.814800E-01 |
| Classical-VS-Follicular |
5.848100E-02 |
| Classical-VS-Other |
1.549850E-01 |
| Classical-VS-Normal |
1.62447832963153E-12 |
| Tall-VS-Follicular |
6.368100E-02 |
| Tall-VS-Other |
1.127400E-01 |
| Tall-VS-Normal |
1.71679999994012E-07 |
| Follicular-VS-Other |
2.542400E-03 |
| Follicular-VS-Normal |
9.86299930616497E-11 |
| Other-VS-Normal |
8.759600E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.62436730732907E-12 |
| Normal-vs-N1 |
3.01639999977787E-07 |
| N0-vs-N1 |
1.826390E-02 |
|
|
